WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In these brooding species, the eggs are relatively large, supplied with yolk, and generally develop directly into miniature starfish without an intervening larval stage, called "lecithotrophic". In Parvulastra parvivipara, an intragonadal brooder, the young starfish obtain nutrients by eating other eggs and embryos in the brood pouch. Brooding occurs in species that live in colder waters, as well as in smaller species that produce just a few eggs. The timing of spawning may be influenced by lighting conditions, water temperature, food availability, and other factors. Individuals may gather together to release their gametes at once, using pheromones to attract each other. In some species, a male and female may come together and form a pair. They engage in pseudocopulation which involves the male crawling on the female; the male fertilises the gametes while the female releases them.
To be a Royal Arch Purpleman, one must be a professing reformed Christian, sober and temperate, not prone to cursing or swearing, and a faithful attender in his Church. Marksman for example within the Royal Arch Purple refers to the Israelites who marked the location of the Ark of the Covenant. The Royal Arch Purple Degree is now established as a separate Order, in Ireland at least, and has over 30,000 members. The collarette of a Royal Arch Purpleman is a collarette of Orange and Purple in which the colour purple predominates. The Royal Arch Purple Degree is now established as a separate Order and is widely practised as a natural step of advancement from the Orange Institution to the Royal Black Institution.
== Channel management == The firm's marketing department needs to design the most suitable channels for the firm's products, then select appropriate channel members or intermediaries. An organization may need to train staff of intermediaries and motivate the intermediary to sell the firm's products. The firm should monitor the channel's performance over time and modify the channel to enhance performance.
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH) or by several other names, is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin inhibits insulin and glucagon secretion. Somatostatin has two active forms produced by the alternative cleavage of a single preproprotein: one consisting of 14 amino acids (shown in infobox to right), the other consisting of 28 amino acids. Alternate cleavage sites of the SST preproprotein results in the production of the hormone Neuronostatin, which has two active forms as Neuronostatin-13 and Neuronostatin-19. Neuronostatin is distinct from Somatostatin in its amino acid sequence, post-translation modifications and receptor binding. Among the vertebrates, there exist six different somatostatin genes that have been named: SS1, SS2, SS3, SS4, SS5 and SS6. Zebrafish have all six. The six different genes, along with the five different somatostatin receptors, allow somatostatin to possess a large range of functions. Humans have only one somatostatin gene, SST.
Sources: en.wikipedia.org
== In plants == The light reactions of photosynthesis generate ATP by the action of chemiosmosis. The photons in sunlight are received by the antenna complex of Photosystem II, which excites electrons to a higher energy level. These electrons travel down an electron transport chain, causing protons to be actively pumped across the thylakoid membrane into the thylakoid lumen. These protons then flow down their electrochemical potential gradient through an enzyme called ATP-synthase, creating ATP by the phosphorylation of ADP to ATP. The electrons from the initial light reaction reach Photosystem I, then are raised to a higher energy level by light energy and then received by an electron acceptor and reduce NADP+ to NADPH. The electrons lost from Photosystem II get replaced by the oxidation of water, which is "split" into protons and oxygen by the oxygen-evolving complex (OEC, also known as WOC, or the water-oxidizing complex). To generate one molecule of diatomic oxygen, 10 photons must be absorbed by Photosystems I and II, four electrons must move through the two photosystems, and 2 NADPH are generated (later used for carbon dioxide fixation in the Calvin Cycle).
Breast augmentation (also breast enlargement) is a plastic surgery procedure by which either a breast implant or a fat-graft implant is emplaced to the thorax to increase the size of the breasts in order to correct congenital defects of the breast and of the chest wall. Consequently, after the breast-enlargement surgery, the symmetrical breast hemisphere is of proportionate size, has a smooth contour, and is anatomically consistent with the woman's body. Three therapeutic purposes require the emplacement of a prosthetic breast: (i) primary reconstruction surgery of the chest and breast tissues damaged by breast cancer, blunt trauma, penetrating trauma, and blast injury; and of developmental defects of the thoracic anatomy, e.g. the tuberous breast deformity; (ii) the surgical revision and reconstruction of chest-and-breast-tissue complications arisen from a previous mammoplasty; and (iii) primary augmentation to surgically enhance the aesthetics of the bust and the breasts. To augment the volume of the breast hemisphere, a prosthetic breast (saline or silicone) establishes the initial spherical augmentation of the breast for contouring by the plastic surgeon. To augment the volume of the breast hemisphere with autologous adipocyte tissue, the surgeon injects the woman's refined body-fat into the skin envelope to correct contour defects of the breast hemisphere. A fat-graft breast augmentation yields a breast-size increase is of modest volume, usually one brassière cup-size, consequent to the body's usual resorbtion of most of the autologous fat-graft.
== External links == "The Science of Drug Use: A Resource for the Justice Sector". www.drugabuse.gov. North Bethesda, Maryland: National Institute on Drug Abuse. 26 May 2020. Retrieved 23 December 2021. School-Based Drug Abuse Prevention: Promising and Successful Programs (PDF). Ottawa, Ontario: Public Safety Canada. 31 January 2018. ISBN 978-1-100-12181-9. Archived (PDF) from the original on 19 May 2021. Retrieved 23 December 2021. {{cite book}}: |website= ignored (help) Sacco LN, Finklea K (3 May 2016). "Synthetic Drugs: Overview and Issues for Congress" (PDF). Washington, D.C.: Congressional Research Service. Archived (PDF) from the original on 8 December 2021. Retrieved 23 December 2021.
A cement is a binder used for construction that sets, hardens, and adheres to other materials to bind them together. Cement is seldom used on its own, but rather to bind sand and gravel (aggregate) together. Cement mixed with fine aggregate produces mortar for masonry, or with sand and gravel, produces concrete. Concrete is the most widely used material in existence and is behind only water as the planet's most-consumed resource. Cements used in construction are usually inorganic, often lime- or calcium silicate-based, and are either hydraulic or less commonly non-hydraulic, depending on the ability of the cement to set in the presence of water (see hydraulic and non-hydraulic lime plaster). Hydraulic cements such as Portland cement set and become adhesive through a chemical reaction between the dry ingredients and water. The chemical reaction results in mineral hydrates that are not very water-soluble. This allows setting in wet conditions or under water and further protects the hardened material from chemical attack. The chemical process for hydraulic cement was found by ancient Romans who used volcanic ash (pozzolana) with added lime (calcium oxide). Non-hydraulic cement does not set in wet conditions or under water. Rather, it sets as it dries and reacts with carbon dioxide in the air. It is resistant to attack by chemicals after setting. World production of cement is about 4.4 billion tonnes per year (2021, estimation), of which about half is made in China, followed by India and Vietnam.
Lymphadenopathy refers to one or more enlarged lymph nodes. Small groups or individually enlarged lymph nodes are generally reactive in response to infection or inflammation. This is called local lymphadenopathy. When many lymph nodes in different areas of the body are involved, this is called generalised lymphadenopathy. Generalised lymphadenopathy may be caused by infections such as infectious mononucleosis, tuberculosis and HIV, connective tissue diseases such as SLE and rheumatoid arthritis, and cancers, including both cancers of tissue within lymph nodes, discussed below, and metastasis of cancerous cells from other parts of the body, that have arrived via the lymphatic system.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.